List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7999555/publications.pdf Version: 2024-02-01



IAE SELING KIM

#	Article	IF	CITATIONS
1	Correlations with REM sleep behavior disorder severity in isolated rapid eye movement sleep behavior disorders patients. International Journal of Neuroscience, 2023, 133, 918-924.	1.6	2
2	60 Years of Achievements by KSNM in Neuroimaging Research. Nuclear Medicine and Molecular Imaging, 2022, 56, 3-16.	1.0	0
3	Role of White Matter Abnormalities in the Relationship Between Microbleed Burden and Cognitive Impairment in Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2022, 86, 667-678.	2.6	3
4	PET-Based Radiogenomics Supports mTOR Pathway Targeting for Hepatocellular Carcinoma. Clinical Cancer Research, 2022, 28, 1821-1831.	7.0	12
5	¹⁸ F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β-Amyloid-Negative Amnestic Mild Cognitive Impairment. Yonsei Medical Journal, 2022, 63, 259.	2.2	5
6	Unified Deep Learning-Based Mouse Brain MR Segmentation: Template-Based Individual Brain Positron Emission Tomography Volumes-of-Interest Generation Without Spatial Normalization in Mouse Alzheimer Model. Frontiers in Aging Neuroscience, 2022, 14, 807903.	3.4	6
7	Diagnostic and prognostic impact of fluorodeoxyglucose-positron emission tomography in diagnosing intraductal papillary neoplasms of the bile duct of the liver. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S297-S297.	0.1	0
8	Diagnostic and prognostic impact of fluorodeoxyglucose-positron emission tomography in diagnosing intraductal papillary neoplasms of the bile duct of the liver. Annals of Surgical Treatment and Research, 2022, 102, 335.	1.0	5

[¹⁸F]THK-5351 PET Patterns in Patients With Alzheimer's Disease and Negative Amyloid PET

#	Article	IF	CITATIONS
19	FDG-PET patterns associated with ideomotor apraxia and imitation apraxia in patients with corticobasal syndrome. Parkinsonism and Related Disorders, 2021, 88, 96-101.	2.2	4
20	Diagnostic accuracy of dual-phase 18F-FP-CIT PET imaging for detection and differential diagnosis of Parkinsonism. Scientific Reports, 2021, 11, 14992.	3.3	14
21	Associations of Circulating Levels of Sphingosine 1-Phosphate with the Trabecular Bone Score and Bone Mineral Density in Postmenopausal Women. Journal of Clinical Densitometry, 2021, 24, 414-421.	1.2	6
22	Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. British Journal of Surgery, 2021, 109, 61-70.	0.3	13
23	Clinical Implications of Amyloid-Beta Accumulation in Occipital Lobes in Alzheimer's Continuum. Brain Sciences, 2021, 11, 1232.	2.3	6
24	Effects of Cognitive Reserve in Alzheimer's Disease and Cognitively Unimpaired Individuals. Frontiers in Aging Neuroscience, 2021, 13, 784054.	3.4	13
25	18F-FDG PET/CT versus CT/MR imaging for detection of neck lymph node metastasis in palpably node-negative oral cavity cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 237-244.	2.5	20
26	Neural and dopaminergic correlates of fatigue in Parkinson's disease. Journal of Neural Transmission, 2020, 127, 301-309.	2.8	7
27	The clinical feasibility of deep learning-based classification of amyloid PET images in visually equivocal cases. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 332-341.	6.4	37
28	Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351. Clinical Nuclear Medicine, 2020, 45, 841-847.	1.3	16
29	Prediction of cervical metastasis and survival in cN0 oral cavity cancer using tumour 18F-FDG PET/CT functional parameters. Journal of Cancer Research and Clinical Oncology, 2020, 146, 3341-3348.	2.5	5
30	Tau Imaging: New Era of Neuroimaging for Alzheimer's Disease. Nuclear Medicine and Molecular Imaging, 2020, 54, 161-162.	1.0	4
31	Areas of white matter hyperintensities and motor symptoms of Parkinson disease. Neurology, 2020, 95, e291-e298.	1.1	24
32	Post-treatment 18F-FDG PET/CT for predicting survival and recurrence in patients with advanced-stage head and neck cancer undergoing curative surgery. Oral Oncology, 2020, 107, 104750.	1.5	7
33	Clinical significance of the post-radiotherapy ¹⁸ F-fludeoxyglucose positron emission tomography response in nasopharyngeal carcinoma. British Journal of Radiology, 2019, 92, 20180045.	2.2	6
34	Differences in gray and white matter 18F-THK5351 uptake between behavioral-variant frontotemporal dementia and other dementias. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 357-366.	6.4	19
35	False-negative Hepatobiliary Scintigraphy for Biliary Atresia. Nuclear Medicine and Molecular Imaging, 2019, 53, 356-360.	1.0	4
36	White matter hyperintensities as a predictor of freezing of gait in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 66, 105-109.	2.2	27

#	Article	IF	CITATIONS
37	Clinical utility of ¹⁸ F-FDG PET/CT for patients with recurrent head and neck squamous cell carcinoma. Acta Oto-Laryngologica, 2019, 139, 810-815.	0.9	4
38	The Local and Systemic Interactions Between Muscle and Bone in Postmenopausal Korean Women. Calcified Tissue International, 2019, 105, 373-382.	3.1	6
39	THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report. BMC Neurology, 2019, 19, 211.	1.8	8
40	Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study. Targeted Oncology, 2019, 14, 689-697.	3.6	7
41	Metabolic tumor volume and total lesion glycolysis predict tumor progression and survival after salvage surgery for recurrent oral cavity squamous cell carcinoma. Head and Neck, 2019, 41, 1846-1853.	2.0	10
42	Chest radiography or chest CT plus head and neck CT versus 18F-FDG PET/CT for detection of distant metastasis and synchronous cancer in patients with head and neck cancer. Oral Oncology, 2019, 88, 109-114.	1.5	25
43	Parkinson Disease-Related Pattern of Glucose Metabolism Associated With the Potential for Motor Improvement After Deep Brain Stimulation. Neurosurgery, 2019, 86, 492-499.	1.1	5
44	Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer. European Journal of Cancer, 2019, 116, 98-106.	2.8	54
45	Distinct clinical features of predominant pre-synaptic and trans-synaptic nigrostriatal dysfunction in multiple system atrophy. Journal of the Neurological Sciences, 2019, 402, 100-106.	0.6	5
46	Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer. Oral Oncology, 2019, 95, 95-99.	1.5	40
47	3â€ ² -Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1713-1722.	6.4	8

48 Qualitative Comparison of Semantic Memory Impairment in Patients with Amnestic Mild Cognitive

#	Article	IF	CITATIONS
55	Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions. Neurological Sciences, 2019, 40, 311-317.	1.9	33
56	Gastrectomy and nigrostriatal dopaminergic depletion in de novo Parkinson's disease. Movement Disorders, 2019, 34, 299-301.	3.9	1
57	Amide proton transfer imaging seems to provide higher diagnostic performance in post-treatment high-grade gliomas than methionine positron emission tomography. European Radiology, 2018, 28, 3285-3295.	4.5	27
58	Risk Estimation for Biliary Atresia in Patients with Neonatal Cholestasis: Development and Validation of a Risk Score. Radiology, 2018, 288, 262-269.	7.3	18
59	Clinical significance of visually equivocal amyloid PET findings from the Alzheimer's Disease Neuroimaging Initiative cohort. NeuroReport, 2018, 29, 553-558.	1.2	6
60	Prediction of distant metastasis and survival in adenoid cystic carcinoma using quantitative 18 F-FDG PET/CT measurements. Oral Oncology, 2018, 77, 98-104.	1.5	19
61	Detection of distant metastasis and prognostic prediction of recurrent salivary gland carcinomas using ¹⁸ Fâ€FDG PET/CT. Oral Diseases, 2018, 24, 940-947.	3.0	12
62	Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease. Parkinsonism and Related Disorders, 2018, 51, 43-48.	2.2	79
63	Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 423-431.	6.4	24
64	Effects of dopaminergic depletion and brain atrophy on neuropsychiatric symptoms in de novo Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 197-204.	1.9	19
65	Early-onset drug-induced parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 169-174.	1.9	14
66	Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 432-442.	6.4	51
67	P2â€359: RELATION NETWORKS OF NEURODEGENERATION IN ALZHEIMER'S DISEASE SPECTRUM: TAU, AMYLOI AND CORTICAL ATROPHY. Alzheimer's and Dementia, 2018, 14, P827.	D, _{0.8}	0
68	P1â€396: COGNITION AND NEUROFIBRILLARY DEGENERATION IN PATIENTS WITH AMYLOIDâ€NEGATIVE MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P454.	0.8	0
69	O1â€14â€03: NATURAL HISTORY OF SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT: AN 8.5â€YEAR LONGIT STUDY. Alzheimer's and Dementia, 2018, 14, P258.	UDINAL	0
70	P3â€089: DATAâ€DRIVEN PATHOLOGICAL POSITIVITY OF ALZHEIMER DISEASE: AN EXPLORATORY STUDY OF DYNAMIC BIOMARKER CAUSALITY. Alzheimer's and Dementia, 2018, 14, P1099.	0.8	0
71	P3â€433: NEURAL SUBSTRATES OF COGNITIVE RESERVE IN THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P1277.	0.8	0
72	Pre-treatment metabolic tumor volume predicts tumor metastasis and progression in high-grade salivary gland carcinoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2485-2493.	2.5	8

#	Article	IF	CITATIONS
73	The impact of education on cortical thickness in amyloid-negative subcortical vascular dementia: cognitive reserve hypothesis. Alzheimer's Research and Therapy, 2018, 10, 103.	6.2	15
74	The presence of depression in de novo Parkinson's disease reflects poor motor compensation. PLoS ONE, 2018, 13, e0203303.	2.5	23
75	The Pattern of Striatal Dopamine Depletion as a Prognostic Marker in De Novo Parkinson Disease. Clinical Nuclear Medicine, 2018, 43, 787-792.	1.3	19
76	Putaminal dopamine depletion in de novo Parkinson's disease predicts future development of wearing-off. Parkinsonism and Related Disorders, 2018, 53, 96-100.	2.2	16
77	Higher sympathetic activity as a risk factor for skeletal deterioration in pheochromocytoma. Bone, 2018, 116, 1-7.	2.9	12
78	Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?. CNS Drugs, 2018, 32, 971-979.	5.9	4
79	The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1585-1595.	6.4	20
80	Prognostic value of ¹⁸ Fâ€FDG PET/CT parameters in patients who undergo salvage treatments for recurrent squamous cell carcinoma of the larynx and hypopharynx. Journal of Surgical Oncology, 2018, 118, 644-650.	1.7	5
81	Total MRI Small Vessel Disease Burden Correlates with Cognitive Performance, Cortical Atrophy, and Network Measures in a Memory Clinic Population. Journal of Alzheimer's Disease, 2018, 63, 1485-1497.	2.6	55
82	Comparison of Videofluoroscopic Swallowing Study and Radionuclide Salivagram for Aspiration Pneumonia in Children With Swallowing Difficulty. Annals of Rehabilitation Medicine, 2018, 42, 52.	1.6	13
83	Additional Value of Early-Phase 18F-FP-CIT PET Image for Differential Diagnosis of Atypical Parkinsonism. Clinical Nuclear Medicine, 2017, 42, e80-e87.	1.3	31
84	Optimized statistical parametric mapping for partial-volume-corrected amyloid positron emission tomography in patients with Alzheimer's disease and Lewy body dementia. Journal of the Korean Physical Society, 2017, 70, 454-459.	0.7	0
85	Regional amyloid burden and lacune in pure subcortical vascular cognitive impairment. Neurobiology of Aging, 2017, 55, 20-26.	3.1	10
86	18F-FDG PET/CT surveillance for the detection of recurrence in patients with head and neck cancer. European Journal of Cancer, 2017, 72, 62-70.	2.8	41
87	Lymph node standardized uptake values at pre-treatment ¹⁸ F-fluorodeoxyglucose positron emission tomography as a valuable prognostic factor for distant metastasis in nasopharyngeal carcinoma. British Journal of Radiology, 2017, 90, 20160239.	2.2	23
88	¹⁸ F-FDG PET/CT <i>vs</i> . human papillomavirus, p16 and Epstein-Barr virus detection in cervical metastatic lymph nodes for identifying primary tumors. International Journal of Cancer, 2017, 140, 1405-1412.	5.1	23
89	Does smoking impact dopamine neuronal loss in de novo Parkinson disease?. Annals of Neurology, 2017, 82, 850-854.	5.3	15
90	18F-FDG PET/CT Versus Contrast-Enhanced CT for Staging and Prognostic Prediction in Patients With Salivary Gland Carcinomas. Clinical Nuclear Medicine, 2017, 42, e149-e156.	1.3	25

#	Article	IF	CITATIONS
91	[P1–129]: PREDICTION MODEL OF TAU PROPAGATION IN AD SPECTRUM USING FUNCTIONAL NETWORK. Alzheimer's and Dementia, 2017, 13, P291.	0.8	0
92	Full automatic synthesis of [18F]THK-5351 for tau protein PET imaging in Alzheimer's disease patients: 1Âyear experience. Journal of Radioanalytical and Nuclear Chemistry, 2017, 314, 1587-1593.	1.5	1
93	[P4–212]: HEADâ€TOâ€HEAD COMPARISON OF [¹⁸ F] AVâ€1451 AND [¹⁸ F] THK53: IMAGING IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1347.	51 FOR TA 0.8	U 1
94	Protective effects of APOE e2 against disease progression in subcortical vascular mild cognitive impairment patients: A three-year longitudinal study. Scientific Reports, 2017, 7, 1910.	3.3	32
95	Longitudinal Decline of Striatal Subregional [18F]FP-CIT Uptake in Parkinson's Disease. Nuclear Medicine and Molecular Imaging, 2017, 51, 304-313.	1.0	12
96	Premorbid exercise engagement and motor reserve in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 34, 49-53.	2.2	25
97	Pretreatment tumor SUVmax predicts disease-specific and overall survival in patients with head and neck soft tissue sarcoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 33-40.	6.4	24
98	[P2–361]: SURFACEâ€BASED ANALYSIS OF SUB ORTICAL STRUCTURES IN TAU AND AMYLOID PET IMAGINO ALZHEIMER'S DISEASE STUDY. Alzheimer's and Dementia, 2017, 13, P762.	: AN 6.8	0
99	[P2–406]: IN VIVO BRAAK STAGING OF AMNESTIC MCI USING ¹⁸ Fâ€THK5351 PET IMAGING. Alzheimer's and Dementia, 2017, 13, P786.	0.8	0
100	[P2–424]: PROTECTIVE EFFECTS OF EDUCATION ON THKâ€5351 UPTAKES IN MILD COGNITIVE IMPAIRMENT W SUSPECTED NONâ€ALZHEIMER PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P798.	ИТН 0.8	0
101	[P3–319]: MILD COGNITIVE IMPAIRMENT CLASSIFICATION USING DEEP LEARNING. Alzheimer's and Dementia, 2017, 13, P1070.	0.8	0
102	[P3–330]: COMPARISON OF QUANTITATIVE TAU DEPOSITION ON THKâ€5351 PET IMAGING AND HIPPOCAMPA VOLUME IN DIAGNOSIS OF ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2017, 13, P1077.	^{\L} 0.8	0
103	[P3–337]: THK5351 UPTAKES IN EARLY AND LATE STAGES OF AMNESTIC MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1082.	0.8	0
104	[P4–046]: PARTIAL VOLUME SUSCEPTIBILITY OF TAU PET: REGIONWISE ASSESSMENT AND COMPARISON WITH AMYLOID PET. Alzheimer's and Dementia, 2017, 13, P1274.	0.8	0
105	[P4–253]: QUANTITATIVE ANALYSIS AND CORRELATION WITH COGNITIVE FUNCTION OF Fâ€18 THKâ€5351 PE SUBJECTIVE MEMORY IMPAIRMENT, MILD COGNITIVE IMPAIRMENT, AND ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1377.	T IN 0.8	0
106	[P1–454]: POSITIVE ASSOCIATION BETWEEN EDUCATION AND THKâ€5351 UPTAKES IN PATIENTS WITH ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P460.	0.8	0
107	[O1–08–01]: PATTERNS OF REGIONAL TAU ACCUMULATION INDICATIVE OF THREE DIFFERENT TYPES OF ALZHEIMER'S DISEASE (AD): THK5351â€PETâ€BASED REPLICATION OF PATHOLOGYâ€BASED AD CLASSIFICATION Alzheimer's and Dementia, 2017, 13, P206.	8.QV	0
108	Striatofrontal Deafferentiation in MSA-P: Evaluation with [18F]FDG Brain PET. PLoS ONE, 2017, 12, e0169928.	2.5	13

#	Article	IF	CITATIONS
109	Different subregional metabolism patterns in patients with cerebellar ataxia by 18F-fluorodeoxyglucose positron emission tomography. PLoS ONE, 2017, 12, e0173275.	2.5	13
110	Asymmetry of cerebral glucose metabolism in very low-birth-weight infants without structural abnormalities. PLoS ONE, 2017, 12, e0186976.	2.5	6
111	Persistent Drug-Induced Parkinsonism in Patients with Normal Dopamine Transporter Imaging. PLoS ONE, 2016, 11, e0157410.	2.5	23
112	Impact of 18F-FDG PET/CT staging on management and prognostic stratification in head and neck squamous cell carcinoma: A prospective observational study. European Journal of Cancer, 2016, 63, 88-96.	2.8	39
113	The Role of Cerebrovascular Disease inÂAmyloid Deposition. Journal of Alzheimer's Disease, 2016, 54, 1015-1026.	2.6	12
114	Distinctive Resting State Network Disruptions Among Alzheimer's Disease, Subcortical Vascular Dementia, and Mixed Dementia Patients. Journal of Alzheimer's Disease, 2016, 50, 709-718.	2.6	41
115	Different loss of dopamine transporter according to subtype of multiple system atrophy. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 517-525.	6.4	34
116	Subregional Pattern of Striatal Dopamine Transporter Loss on ¹⁸ F FP-CIT Positron Emission Tomography in Patients With Pure Akinesia With Gait Freezing. JAMA Neurology, 2016, 73, 1477.	9.0	24
117	Synergistic effects of longitudinal amyloid and vascular changes on lobar microbleeds. Neurology, 2016, 87, 1575-1582.	1.1	28
118	Relative impact of amyloid-β, lacunes, and downstream imaging markers on cognitive trajectories. Brain, 2016, 139, 2516-2527.	7.6	51
119	Early- vs late-onset subcortical vascular cognitive impairment. Neurology, 2016, 86, 527-534.	1.1	18
120	Synthesis and evaluation of 6-(3-[18F]fluoro-2-hydroxypropyl)-substituted 2-pyridylbenzothiophenes and 2-pyridylbenzothiazoles as potential PET tracers for imaging Aβ plaques. Bioorganic and Medicinal Chemistry, 2016, 24, 2043-2052.	3.0	15
121	¹⁸ F FDG PET/CT versus CT/MR Imaging and the Prognostic Value of Contralateral Neck Metastases in Patients with Head and Neck Squamous Cell Carcinoma. Radiology, 2016, 279, 481-491.	7.3	40
122	Association of body mass index and the depletion of nigrostriatal dopamine in Parkinson's disease. Neurobiology of Aging, 2016, 38, 197-204.	3.1	36
123	Software development for ACR-approved phantom-based nuclear medicine tomographic image quality control with cross-platform compatibility. Journal of the Korean Physical Society, 2015, 67, 323-328.	0.7	0
124	Effects of Amyloid and Small Vessel Disease on White Matter Network Disruption. Journal of Alzheimer's Disease, 2015, 44, 963-975.	2.6	29
125	Preserved Hippocampal Glucose Metabolism on ¹⁸ F-FDG PET after Transplantation of Human Umbilical Cord Blood-derived Mesenchymal Stem Cells in Chronic Epileptic Rats. Journal of Korean Medical Science, 2015, 30, 1232.	2.5	6
126	¹⁸ Fâ€fluoromisonidazole (FMISO) Positron Emission Tomography (PET) Predicts Early Infarct Growth in Patients with Acute Ischemic Stroke. Journal of Neuroimaging, 2015, 25, 652-655.	2.0	8

#	Article	IF	CITATIONS
127	Detection of Occult Primary Tumors in Patients with Cervical Metastases of Unknown Primary Tumors: Comparison of ¹⁸ F FDG PET/CT with Contrast-enhanced CT or CT/MR Imaging—Prospective Study. Radiology, 2015, 274, 764-771.	7.3	80
128	Clinical effect of white matter network disruption related to amyloid and small vessel disease. Neurology, 2015, 85, 63-70.	1.1	79
129	Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography. Neurological Sciences, 2015, 36, 269-274.	1.9	15
130	Amyloid burden, cerebrovascular disease, brain atrophy, and cognition in cognitively impaired patients. Alzheimer's and Dementia, 2015, 11, 494.	0.8	61
131	Prognostic significance of standardized uptake value and metabolic tumour volume on 18F-FDG PET/CT in oropharyngeal squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1353-1361.	6.4	34
132	Intratumor Textural Heterogeneity on Pretreatment 18F-FDG PET Images Predicts Response and Survival After Chemoradiotherapy for Hypopharyngeal Cancer. Annals of Surgical Oncology, 2015, 22, 2746-2754.	1.5	43
133	Preoperative Contrast-Enhanced CT Versus 18F-FDG PET/CT Evaluation and the Prognostic Value of Extranodal Extension for Surgical Patients with Head and Neck Squamous Cell Carcinoma. Annals of Surgical Oncology, 2015, 22, 1020-1027.	1.5	14
134	Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. Neurology, 2015, 85, 1687-1693.	1.1	44
135	Is <scp>D</scp> ominantâ€ <scp>S</scp> ide <scp>O</scp> nset <scp>A</scp> ssociated <scp>W</scp> ith a <scp>B</scp> etter <scp>M</scp> otor <scp>C</scp> ompensation in <scp>P</scp> arkinson's <scp>D</scp> isease?. Movement Disorders, 2015, 30, 1921-1925.	3.9	47
136	Is normosmic Parkinson disease a unique clinical phenotype?. Neurology, 2015, 85, 1270-1275.	1.1	53
137	Hippocampal volume and shape in pure subcortical vascular dementia. Neurobiology of Aging, 2015, 36, 485-491.	3.1	37
138	The utility of susceptibility-weighted imaging for differentiating Parkinsonism-predominant multiple system atrophy from Parkinson's disease: Correlation with 18F-flurodeoxyglucose positron-emission tomography. Neuroscience Letters, 2015, 584, 296-301.	2.1	34
139	Uneven age effects of [18F]FP-CIT binding in the striatum of Parkinson's disease. Annals of Nuclear Medicine, 2014, 28, 874-879.	2.2	12
140	The Effect of SSRIs on the Binding of 18F-FP-CIT in Parkinson Patients: A Retrospective Case Control Study. Nuclear Medicine and Molecular Imaging, 2014, 48, 287-294.	1.0	13
141	¹⁸ F Fluorodeoxyglucose PET/CT in Head and Neck Squamous Cell Carcinoma with Negative Neck Palpation Findings: A Prospective Study. Radiology, 2014, 271, 153-161.	7.3	83
142	Neural correlates of progressive reduction of bradykinesia in de novo Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 1376-1381.	2.2	35
143	Cerebellum-specific 18F-FDG PET analysis for the detection of subregional glucose metabolism changes in spinocerebellar ataxia. NeuroReport, 2014, 25, 1198-1202.	1.2	29
144	Synergistic Effects of Ischemia and β-Amyloid Burden on Cognitive Decline in Patients With Subcortical Vascular Mild Cognitive Impairment. JAMA Psychiatry, 2014, 71, 412.	11.0	90

#	Article	IF	CITATIONS
145	Identification of Ambiguous Activities in Radionuclide Cisternography Using SPECT/CT: Aspirated and Ingested CSF Rhinorrhea. Nuclear Medicine and Molecular Imaging, 2014, 48, 87-88.	1.0	0
146	Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by 18F-FDG PET/CT in squamous cell carcinoma of the oral cavity. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 452-461.	6.4	53
147	Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology, 2014, 82, 1597-1604.	1.1	78
148	Dopaminergic modulation of restingâ€ s tate functional connectivity in de novo patients with Parkinson's disease. Human Brain Mapping, 2014, 35, 5431-5441.	3.6	30
149	Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment. Neurobiology of Aging, 2014, 35, 254-260.	3.1	70
150	Clinical values for abnormal 18F-FDG uptake in the head and neck region of patients with head and neck squamous cell carcinoma. European Journal of Radiology, 2014, 83, 1455-1460.	2.6	11
151	White Matter Hyperintensities are associated with Amyloid Burden in APOE4 Non-Carriers. Journal of Alzheimer's Disease, 2014, 40, 877-886.	2.6	34
152	Clinical significance of pretreatment metabolic tumor volume and total lesion glycolysis in hypopharyngeal squamous cell carcinomas. Journal of Surgical Oncology, 2014, 110, 869-875.	1.7	22
153	P2-208: INCIDENT CEREBRAL MICROBLEEDS IN SUBJECTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT: LONGITUDINAL STUDY. , 2014, 10, P548-P549.		0
154	O5-01-01: EFFECTS OF AMYLOID AND CEREBROVASCULAR DISEASE ON ALTERED WHITE MATTER NETWORK IN COGNITIVELY IMPAIRED PATIENTS. , 2014, 10, P286-P287.		0
155	IC-P-017: BLINDED VISUAL EVALUATION AND QUANTITATIVE SUVR THRESHOLD CLASSIFICATION OF [18F]FLUTEMETAMOL PET IMAGES IN JAPANESE SUBJECTS. , 2014, 10, P15-P15.		1
156	P3-217: BLINDED VISUAL EVALUATION AND QUANTITATIVE SUVR THRESHOLD CLASSIFICATION OF [18F]FLUTEMETAMOL PET IMAGES IN JAPANESE SUBJECTS. , 2014, 10, P710-P710.		0
157	IC-P-186: EFFECTS OF AMYLOID AND CEREBROVASCULAR DISEASE ON ALTERED WHITE MATTER NETWORK IN COGNITIVELY IMPAIRED PATIENTS. , 2014, 10, P103-P104.		0
158	18F-Fluorodeoxyglucose Positron-Emission Tomography Findings with Anti-N-Methyl-D-Aspartate Receptor Encephalitis that Showed Variable Degrees of Catatonia: Three Cases Report. Journal of Epilepsy Research, 2014, 4, 69-73.	0.4	13
159	Clinical and neuroimaging characteristics in neurodegenerative overlap syndrome. Neurological Sciences, 2013, 34, 875-881.	1.9	8
160	Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging. Nuclear Medicine and Molecular Imaging, 2013, 47, 44-51.	1.0	57
161	Comparison between the radionuclide salivagram and videofluoroscopic swallowing study methods for evaluating patients with aspiration pneumonia. Annals of Nuclear Medicine, 2013, 27, 247-252.	2.2	16
162	The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments. Neurobiology of Aging, 2013, 34, 1913-1920.	3.1	53

#	Article	IF	CITATIONS
163	Effects of APOE É›4 on brain amyloid, lacunar infarcts, and white matter lesions: aÂstudy among patients with subcortical vascular cognitive impairment. Neurobiology of Aging, 2013, 34, 2482-2487.	3.1	20
164	Ictal singing due to right mesial temporal lobe epilepsy involving a bihemispheric network. Epilepsy & Behavior Case Reports, 2013, 1, 85-88.	1.5	4
165	Pathogenesis of cerebral microbleeds: In vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Annals of Neurology, 2013, 73, 584-593.	5.3	146
166	Cognitive deficits of pure subcortical vascular dementia vs Alzheimer disease. Neurology, 2013, 80, 569-573.	1.1	44
167	Utility of 18F-FDG PET/CT for Detecting Neck Metastasis in Patients with Salivary Gland Carcinomas: Preoperative Planning for Necessity and Extent of Neck Dissection. Annals of Surgical Oncology, 2013, 20, 899-905.	1.5	39
168	Clinical features and nigrostriatal dysfunction in patients with combined postural and resting tremors. Parkinsonism and Related Disorders, 2013, 19, 1118-1122.	2.2	3
169	Prognostic Value of Preoperative Metabolic Tumor Volume and Total Lesion Glycolysis Measured by ¹⁸ F-FDG PET/CT in Salivary Gland Carcinomas. Journal of Nuclear Medicine, 2013, 54, 1032-1038.	5.0	70
170	3′-Deoxy-3′-18F-Fluorothymidine PET for the Early Prediction of Response to Leucovorin, 5-Fluorouracil, and Oxaliplatin Therapy in Patients with Metastatic Colorectal Cancer. Journal of Nuclear Medicine, 2013, 54, 1209-1216.	5.0	26
171	Amyloid Deposition in Early Onset versus Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 35, 813-821.	2.6	57
172	Individual Subject Classification of Mixed Dementia from Pure Subcortical Vascular Dementia Based on Subcortical Shape Analysis. PLoS ONE, 2013, 8, e75602.	2.5	8
173	Diagnostic Value of Neck Node Status Using ¹⁸ F-FDG PET for Salivary Duct Carcinoma of the Major Salivary Glands. Journal of Nuclear Medicine, 2012, 53, 881-886.	5.0	24
174	Cortical Thinning in Subcortical Vascular Dementia with Negative 11C-PiB PET. Journal of Alzheimer's Disease, 2012, 31, 315-323.	2.6	37
175	H-type Tracheoesophageal Fistula Detected by Radionuclide Salivagram. Nuclear Medicine and Molecular Imaging, 2012, 46, 227-229.	1.0	2
176	Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy. Journal of Nuclear Medicine, 2012, 53, 399-406.	5.0	227
177	Laryngeal edema after radiotherapy in patients with squamous cell carcinomas of the larynx and hypopharynx. Oral Oncology, 2012, 48, 853-858.	1.5	25
178	Changes in glucose metabolism and metabolites during the epileptogenic process in the lithiumâ€pilocarpine model of epilepsy. Epilepsia, 2012, 53, 860-869.	5.1	57
179	Effect of Animal Condition and Fluvoxamine on the Result of [18F]N-3-Fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) Nortropane ([18F]FP-CIT) PET Study in Mice. Nuclear Medicine and Molecular Imaging, 2012, 46, 27-33.	1.0	8
180	Nigrostriatal dysfunction in patients with amyotrophic lateral sclerosis and parkinsonism. Journal of the Neurological Sciences, 2011, 301, 12-13.	0.6	17

#	Article	IF	CITATIONS
181	New automated synthesis of [18F]FP-CIT with base amount control affording high and stable radiochemical yield: a 1.5-year production report. Nuclear Medicine and Biology, 2011, 38, 593-597.	0.6	19
182	Diagnostic Usefulness of 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography in Recurrent Brain Tumor. Journal of Computer Assisted Tomography, 2011, 35, 679-684.	0.9	19
183	Combined [18F]fluorodeoxyglucose positron emission tomography and computed tomography for detecting contralateral neck metastases in patients with head and neck squamous cell carcinoma. Oral Oncology, 2011, 47, 376-380.	1.5	39
184	Evaluation of 18F-FDG PET/CT and CT/MRI with Histopathologic Correlation in Patients Undergoing Salvage Surgery for Head and Neck Squamous Cell Carcinoma. Annals of Surgical Oncology, 2011, 18, 2579-2584.	1.5	39
185	Usefulness of Interim FDG-PET After Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Sequential Induction Chemotherapy Followed by Concurrent Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics. 2011. 81. 118-125.	0.8	25
186	PET/CT Fusion Viewing Software for Use with Picture Archiving and Communication Systems. Journal of Digital Imaging, 2010, 23, 732-743.	2.9	14
187	18F-FDG PET/CT is Useful for Pretreatment Assessment of the Histopathologic Type of Thymic Epithelial Tumors. Nuclear Medicine and Molecular Imaging, 2010, 44, 177-184.	1.0	21
188	Imaging Atherosclerosis in the Carotid Arteries with F-18-Fluoro-2-deoxy-D-glucose Positron Emission Tomography: Effect of Imaging Time after Injection on Quantitative Measurement. Nuclear Medicine and Molecular Imaging, 2010, 44, 261-266.	1.0	10
189	Molecular Imaging in Neurodegenerative Diseases. Journal of the Korean Medical Association, 2009, 52, 151.	0.3	3
190	Utility of combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncology, 2009, 45, 218-224.	1.5	112
191	Relationship between hypometabolic patterns and ictal scalp EEG patterns in patients with unilateral hippocampal sclerosis: An FDG–PET study. Epilepsy Research, 2009, 84, 187-193.	1.6	23
192	Comparison of Cerebral Glucose Metabolism between Possible and Probable Multiple System Atrophy. Journal of Movement Disorders, 2009, 2, 22-28.	1.3	4
193	Prediction of prognosis using standardized uptake value of 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiotherapy and Oncology, 2008, 87, 211-216.	0.6	97
194	Prognostic Value of Tumor ¹⁸ F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck. Journal of Nuclear Medicine, 2008, 49, 1783-1789.	5.0	68
195	Use of 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Rare Head and Neck Cancers. Clinical and Experimental Otorhinolaryngology, 2008, 1, 103.	2.1	14
196	Use of 18F-FDG PET for Primary Treatment Strategy in Patients with Squamous Cell Carcinoma of the Oropharynx. Journal of Nuclear Medicine, 2007, 48, 752-757.	5.0	80
197	One-step high-radiochemical-yield synthesis of [18F]FP-CIT using a protic solvent system. Nuclear Medicine and Biology, 2007, 34, 345-351.	0.6	58
198	Ictal Hyperperfusion Patterns in Relation to Ictal Scalp EEG Patterns in Patients with Unilateral Hippocampal Sclerosis: A SPECT Study. Epilepsia, 2007, 48, 270-277.	5.1	29

#	Article	IF	CITATIONS
199	Utility of 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncology, 2007, 43, 887-893.	1.5	125
200	Clinical utility of 18F-FDG PET for patients with salivary gland malignancies. Journal of Nuclear Medicine, 2007, 48, 240-6.	5.0	66
201	A New Class of SN2 Reactions Catalyzed by Protic Solvents:Â Facile Fluorination for Isotopic Labeling of Diagnostic Molecules. Journal of the American Chemical Society, 2006, 128, 16394-16397.	13.7	296
202	[18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 653-659.	6.4	170
203	The usefulness of hepatobiliary scintigraphy in the diagnosis of complications after adult-to-adult living donor liver transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 473-479.	6.4	35
204	Hepatobiliary scintigraphy in the assessment of biliary obstruction after hepatic resection with biliary-enteric anastomosis. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 170-175.	6.4	8